New regulatory and signal functions for myristic acid;Acide myristique: Nouvelles fonctions de régulation et de signalisation

Medecine/Sciences

Volumn 25, Issue 1, 2009, Pages 57-63

  Beauchamp, Erwan ^a   Rioux, Vincent ^a   Legrand, Philippe ^a  

^a Agrocampus French National Institute of Health and Medical Research   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58849143451     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925157     Document Type: Review

References (51)

1. Katan MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an overview. Am J Clin Nutr 1994 ; 60 : 51017-22.
2. Gnädig S, Chardigny JM, Sébédio JL. Lipides. In : Lait, Nutrition et Santé. Paris : Lavoisier Éditions, 2001.
3. Rioux V, Catheline D, Legrand P. In rat hepatocytes, myristic acid occurs through lipogenesis, palmitic shortening and lauric acid elongation. Animal 2007 ; 1 : 820-6.
4. Rioux V, Lemarchal P, Legrand P. Myristic acid, unlike palmitic acid, is rapidly metabolized in cultured rat hepatocytes. J Nutr Biochem 2000 ; 11 : 198-207.
5. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992 ; 12 : 911-9.
6. Tholstrup T, Vessby B, Sandstrom B. Difference in effect of myristic and stearic acid on plasma HDL cholesterol within 24 h in young men. Eur J Clin Nutr 2003 ; 57 : 735-42.
7. Rioux V, Catheline D, Bouriel M, Legrand P. Dietary myristic acid at physiologically relevant levels increases the tissue content of C20:5 n-3 and C20:3 n-6 in the rat. Reprod Nutr Dev 2005 ; 45 : 599-612.
8. Johnson DR, Bhatnagar RS, Knoll LJ, Gordon JI. Genetic and biochemical studies of protein N-myristoylation. Annu Rev Biochem 1994 ; 63 : 869-914.
9. Giang DK, Cravatt BF. A second mammalian N-myristoyltransferase. J Biol Chem 1998 ; 273 : 6595-8.
10. McIlhinney RA, Young K, Egerton M, et al. Characterization of human and rat brain myristoyl-CoA:protein N-myristoyltransferase: evidence for an alternative splice variant of the enzyme. Biochem J 1998 ; 333 : 491-5.
11. Rioux V, Beauchamp E, Pedrono F, et al. Identification and characterization of recombinant and native rat myristoyl-CoA: protein N-myristoyltransferases. Mol Cell Biochem 2006 ; 286 : 161-70.
12. Kishore NS, Lu TB, Knoll LJ, et al. The substrate specificity of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase. Analysis of myristic acid analogs containing oxygen, sulfur, double bonds, triple bonds, and/or an aromatic residue. J Biol Chem 1991 ; 266 : 8835-55.
13. Bhatnagar RS, Futterer K, Waksman G, Gordon JI. The structure of myristoyl-CoA:protein N-myristoyltransferase. Biochim Biophys Acta 1999 ; 1441 : 162-72.
14. Faergeman NJ, Knudsen J. Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signalling. Biochem J 1997 ; 323 : 1-12.
15. Rioux V, Galat A, Jan G, et al. Exogenous myristic acid acylates proteins in cultured rat hepatocytes. J Nutr Biochem 2002 ; 13 : 66-74.
16. Duronio RJ, Rudnick DA, Johnson RL, et al. Myristic acid auxotrophy caused by mutation of S. cerevisiae myristoyl-CoA:protem N-myristoyltransferase. J Cell Biol 1991 ; 113 : 1313-30.
17. Kokame K, Fukada Y, Yoshizawa T, et al. Lipid modification at the N terminus of photoreceptor G-protein alpha-subunit. Nature 1992 ; 359 : 749-52.
18. DeMar JC Jr, Anderson RE. Identification and quantitation of the fatty acids composing the CoA ester pool of bovine retina, heart, and liver. J Biol Chem 1997 ; 272 : 31362-8.
19. Zha J, Weiler S, Oh KJ, et al. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 2000 ; 290 : 1761-5.
20. Maurer-Stroh S, Gouda M, Novatchkova M, et al. MYRbase: analysis of genome-wide glycine myristoylation enlarges the functional spectrum of eukaryotic myristoylated proteins. Genome Biol 2004 ; 5 : R21.
21. Boutin JA. Myristoylation. Cell Signal 1997 ; 9 : 15-35.
22. Ntwasa M, Aapies S, Schiffmann DA, Gay NJ. Drosophila embryos lacking N-myristoyltransferase have multiple developmental defects. Exp Cell Res 2001 ; 262 : 134-44.
23. Yang SH, Shrivastav A, Kosinski C, et al. N-myristoyltransferase 1 is essential in early mouse development. J Biol Chem 2005 ; 280 : 18990-5.
24. Sennequier N, Vadon-Le Goff S. Biosynthèse de monoxyde d'azote (NO) : mécanisme, régulation et contrôle. Med Sci (Paris) 1998 ; 14 : 1185-95.
25. Shaul PW, Smart EJ, Robinson LJ, et al. Acylation targets endothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 1996 ; 271 : 6518-22.
26. Busconi L, Michel T. Endothelial nitric oxide synthase. N-termmal myristoylation determines subcellular localization. J Biol Chem 1993 ; 268 : 8410-3.
27. Robinson LJ, Busconi L, Michel T. Agonist-modulated palmitoylation of endothelial nitric oxide synthase. J Biol Chem 1995 ; 270 : 995-8.
28. Gonzalez E, Kou R, Lin AJ, et al. Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric oxide synthase. J Biol Chem 2002 ; 277 : 39554-60.
29. Zhu W, Smart EJ. Myristic acid stimulates endothelial nitric-oxide synthase in a CD36-and an AMP kinase-dependent manner. J Biol Chem 2005 ; 280 : 29543-50.
30. Laugerette F, Passilly-Degrace P, Patris B, Niot I, Montmayeur JP, Besnard P. CD36, un sérieux jalon sur la piste du goût du gras. Med Sci (Paris) 2006 ; 22 : 357-9.
31. Isenberg JS, Jia Y, Fukuyama J, et al. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 2007 ; 282 : 15404-15.
32. Gong M, Wilson M, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003 ; 111 : 1579-87.
33. White J, Guerin T, Swanson H, et al. Diabetic HDL-associated myristic acid inhibits acetylcholine-induced nitric oxide generation by preventing the association of endothelial nitric oxide synthase with calmodulin. Am J Physiol Cell Physiol 2008 ; 294 : C295-305.
34. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 2004 ; 39 : 212-20.
35. Bourre JM. Enrichissement de l'alimentation des animaux avec les acides gras omega-3 : impact sur la valeur nutritionnelle de leurs produits pour l'homme. Med Sci (Paris) 2005 ; 21 : 773-9.
36. Jan S, Guillou H, D'Andrea S, et al. Myristic acid increases delta6-desaturase activity in cultured rat hepatocytes. Reprod Nutr Dev 2004 ; 44 : 131-40.
37. Rioux V, Catheline D, Beauchamp E, et al. Substitution of dietary oleic for myristic acid increases the tissue storage of alfa-linolemc acid and the concentration of docosahexaenoic acid in brain, red blood cells and plama in the rat. Animal 2008 ; 2 : 636-44.
38. Porta N, Auvin S. Acides gras polyinsaturés: proprié tés et mécanismes anticonvulsivants. Med Sci (Paris) 2009 ; 25 : 51-6.
39. Dabadie H, Peuchant E, Bernard M, et al. Moderate intake of myristic acid in sn-2 position has beneficial lipidic effects and enhances DHA of cholesteryl esters in an interventional study. J Nutr Biochem 2005 ; 16 : 375-82.
40. Beauchamp E, Goenaga D, Le Bloc'h J, et al. Myristic acid increases the activity of dihydroceramide Delta4-desaturase 1 through its N-terminal myristoylation. Biochimie 2007 ; 89 : 1553-61.
41. Borgese N, Aggujaro D, Carrera P, et al. A role for N-myristoylation in protein targeting: NADH-cytochrome b5 reductase requires myristic acid for association with outer mitochondrial but not ER membranes. J Cell Biol 1996 ; 135 : 1501-13.
42. Stiban J, Fistere D, Colombini M. Dihydroceramide hinders ceramide channel formation: implications on apoptosis. Apoptosis 2006 ; 11 : 773-80.
43. Corbin A, Grigorov B, Roingeard P, et al. Une nouvelle vision de l'assemblage du VIH-1. Med Sci (Paris) 2008 ; 24 : 49-55.
44. nd, et al. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1 : posttranslational modifications, proteolytic processings, and complete amino acid sequences. J Virol 1992 ; 66 : 1856-65.
45. Schultz AM, Oroszlan S. In vivo modification of retroviral gag gene-encoded polyproteins by myristic acid. J Virol 1983 ; 46 : 355-61.
46. Takamune N, Gota K, Misumi S, et al. HIV-1 production is specifically associated with human NMT1 long form in human NMT isozymes. Microbes Infect 2008 ; 10 : 143-50.
47. Seaton KE, Smith CD. N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef. J Gen Virol 2008 ; 89 : 288-96.
48. Spearman P, Horton R, Ratner L, Kuli-Zade I. Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol 1997 ; 71 : 6582-92.
49. Boutin JA. La N-myristoyl transferase, carrefour entre virologie et oncologie: une voie d'accès à des anticancéreux et à des antiviraux d'un genre nouveau? Med Sci (Paris) 1993 ; 9 : 684-92.
50. Lindwasser OW, Resh MD. Myristoylation as a target for inhibiting HIV assembly: unsaturated fatty acids block viral budding. Proc Natl Acad Sci USA 2002 ; 99 : 13037-42.
51. Morikawa Y, Hinata S, Tomoda H, et al. Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding. J Biol Chem 1996 ; 271 : 2868-73.